| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | B2M |
| Uniprot No | P61769 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-119aa |
| 氨基酸序列 | MSRSVALAVLALLSLSGLEAIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于B2M(β2-微球蛋白)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Production of recombinant human beta-2-microglobulin in Escherichia coli and its structural characterization*
**作者**：Smith A, et al.
**摘要**：本研究报道了通过大肠杆菌表达系统高效生产重组人B2M的方法，并利用核磁共振(NMR)分析了其三维结构，证实重组蛋白与天然B2M具有相同的构象和稳定性。
2. **文献名称**：*Role of beta-2-microglobulin in amyloid fibril formation: Insights from recombinant protein studies*
**作者**：Lee JH, et al.
**摘要**：通过体外实验验证重组B2M在透析相关淀粉样变性中的作用，发现特定理化条件(如酸性pH)下，重组B2M可自发形成淀粉样纤维，为疾病机制研究提供模型。
3. **文献名称**：*Enhancing MHC class I antigen presentation using engineered beta-2-microglobulin*
**作者**：Zhang Y, et al.
**摘要**：通过基因工程改造重组B2M，提高其与MHC I类分子的结合效率，从而增强肿瘤细胞表面抗原呈递，为癌症免疫治疗策略的开发提供了新思路。
---
**备注**：以上文献为示例性质，实际文献需通过学术数据库(如PubMed、Web of Science)检索。若需具体文章，建议以关键词“recombinant beta-2-microglobulin”结合研究领域(如“amyloidosis”“MHC-I”“expression”)进一步筛选。
Beta-2-microglobulin (B2M), a 12-kDa protein encoded by the *B2M* gene, is a critical component of the major histocompatibility complex (MHC) class I molecules. These molecules are expressed on nearly all nucleated cells and play a central role in antigen presentation to immune cells, particularly cytotoxic T lymphocytes. Structurally, B2M non-covalently associates with the heavy chain of MHC class I, stabilizing its conformation and enabling peptide loading for immune surveillance. Beyond its immunological role, B2M is implicated in various pathological conditions. Elevated serum levels of B2M are observed in inflammatory diseases, autoimmune disorders, and certain cancers, making it a potential biomarker for disease progression or therapeutic response.
Recombinant B2M protein, produced via genetic engineering in systems like *E. coli* or mammalian cell cultures, retains the native protein's functional properties while enabling standardized production for research and clinical applications. Its recombinant form is widely used in structural studies to investigate MHC class I assembly mechanisms, in immunological assays to study T cell activation, and in cancer research to explore immune evasion strategies. Notably, B2M deficiency has been linked to impaired antigen presentation in tumors, a finding that has spurred interest in B2M-targeted therapies to enhance cancer immunotherapies.
In neurodegenerative contexts, B2M aggregation contributes to dialysis-related amyloidosis, driving research into recombinant B2M as a model for studying protein misfolding. Recent advances in protein engineering have also enabled the development of modified B2M variants for targeted drug delivery or as fusion partners in biotherapeutics. Despite its small size, B2M’s multifaceted roles in health and disease continue to make recombinant B2M a valuable tool for both basic science and translational applications.
×
